Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Exenatide in acute ischemic stroke
Phase III is the commercialization phase and receives no specific SBIR funds, though some agencies do have matching and follow-up funding
Monitoring considerations include: Blood pressure and heart rate monitoring, with potential adjustment of antihypertensive medications Assessment of electrolytes in patients at risk (those taking diuretics or with significant gastrointestinal symptoms) Targeted cardiovascular assessment based on symptoms and risk factors Gradual dose titration to minimize adverse effects and allow cardiovascular adaptation The CDC recommends that weight loss proceed at 1-2 pounds per week for safety
This double-blind, placebo-controlled study randomized adults with a BMI 30 or 27 plus at least one obesity-related comorbidity (excluding diabetes) who had achieved 5% weight loss after 12 weeks of lifestyle modification to receive tirzepatide or placebo weekly for 72 weeks
Ozempic is used for diabetes, while Wegovy is specifically approved for weight loss
US$ 26.42
US$ 29.79
US$ 28.68
US$ 22.81
US$ 20.72
US$ 20.59
US$ 26.35
